Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives …
HAAM Van Vliet, M Frolich, M Christella… - Human …, 2005 - academic.oup.com
BACKGROUND: Epidemiological studies have shown that both the estrogen dose and
progestogen type of oral contraceptives contribute to the increased risk of thrombosis in oral …
progestogen type of oral contraceptives contribute to the increased risk of thrombosis in oral …
[PDF][PDF] Pulmonary embolism: pathophysiology, diagnosis, treatment
E Kostadima, E Zakynthinos - Hellenic J Cardiol, 2007 - hellenicjcardiol.org
Review Article latory support) increase VE, and indeed to a greater extent than is required
for CO2 removal (ie increase VC, too), resulting in hypocapnia. Conversely, in patients with …
for CO2 removal (ie increase VC, too), resulting in hypocapnia. Conversely, in patients with …
Drug-induced thrombosis: an update
Y Ramot, A Nyska, G Spectre - Drug safety, 2013 - Springer
Drugs may play an important role in development of thrombosis, and in recent years there
has been increased attention to the importance of this issue. Although drug-induced …
has been increased attention to the importance of this issue. Although drug-induced …
Oral contraceptive use and increased plasma concentration of C-reactive protein
DM Dreon, JL Slavin, SD Phinney - Life sciences, 2003 - Elsevier
We examined, in young adult women, the association between current low dose oral
contraceptive (OC) use and plasma levels of C-reactive protein (CRP), an acute phase …
contraceptive (OC) use and plasma levels of C-reactive protein (CRP), an acute phase …
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer
C Duggan, K Marriott, R Edwards… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Venous thromboembolism (VTE) is of particular concern in women receiving
tamoxifen in a chemopreventive setting. We investigate the association between acquired …
tamoxifen in a chemopreventive setting. We investigate the association between acquired …
Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study
INTRODUCTION:: The transdermal patch (20 µg ethinylestradiol+ 150 µg norelgestromin
daily) and the vaginal ring (15 µg ethinylestradiol+ 120 µg etonogestrel daily) are new …
daily) and the vaginal ring (15 µg ethinylestradiol+ 120 µg etonogestrel daily) are new …
Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST)
JM Foidart, U Gaspard, C Pequeux, M Jost… - Sex Steroids' Effects on …, 2019 - Springer
Estrogens (E), in oral contraceptives (COCs) and hormone replacement therapy (HRT)
drugs used for the relief of climacteric symptoms of menopause, increase the synthesis of …
drugs used for the relief of climacteric symptoms of menopause, increase the synthesis of …
[HTML][HTML] Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor
H Van Vliet, RM Bertina, AEA Dahm… - Journal of Thrombosis …, 2008 - Elsevier
Background: Oral contraceptives (OC) containing different types of progestogens induce
different sensitivities to activated protein C (APC) measured with the thrombin generation …
different sensitivities to activated protein C (APC) measured with the thrombin generation …
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial
E Høibraaten, MC Mowinckel… - British journal of …, 2001 - Wiley Online Library
Recent studies suggest that low‐dose oral contraceptives may cause acquired resistance to
activated protein C (APC). The aims of this study were to determine whether hormone …
activated protein C (APC). The aims of this study were to determine whether hormone …
New evidence regarding hormone replacement therapies is urgently required: transdermal postmenopausal hormone therapy differs from oral hormone therapy in …
MG Modena, P Sismondi, AO Mueck, F Kuttenn… - Maturitas, 2005 - Elsevier
Controversies about the safety of different postmenopausal hormone therapies (HTs) started
30 years ago and reached a peak in 2003 after the publication of the results from the …
30 years ago and reached a peak in 2003 after the publication of the results from the …